De novo sequencing is the process of determining the amino acid sequence of a protein based directly on the fragment ions detected in the mass spectrometer. Using special algorithms, our analysis software can interpret and assign the sequences without prior database knowledge from the protein. De novo sequencing is often used for bio-similar antibody characterization, developing drugs toward commercially antibody reagentsor resolving ambiguity from gene sequencing of the mAb.
CovalX has access to a full range of the latest mass spectrometry equipment with both MALDI and ESI ionization. Sequencing is typically conducted using high resolution nano-LC OrbiTrap detection.